This pathway is also a major target for KRAS/TP53 mutations to cooperatively promote malignancy in pancreatic ductal adenocarcinoma (PDAC), and is closely associated with immune evasion. This evidence concerns the gene TP53 and pancreatic ductal adenocarcinoma.